Rhinitis, Allergic, Perennial Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Long-term Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, Once Daily) in Adult and Adolescent Subjects (12 Years of Age and Older) With Perennial Allergic Rhinitis (PAR)
Verified date | December 2021 |
Source | Teva Branded Pharmaceutical Products R&D, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Subjects with perennial allergic rhinitis will be randomized to 320 mcg of beclomethasone dipropionate (BDP) using a hydrofluoroalkane (HFA) propellant or placebo as a nasal aerosol. The subjects will be followed for safety and efficacy for a period of 30 or 52 weeks. BDP HFA is a steroid which is currently FDA approved for the treatment of asthma. BDP-HFA should be safe and effective as a "dry" nasal aerosol which may be preferred by some patients.
Status | Completed |
Enrollment | 529 |
Est. completion date | February 28, 2011 |
Est. primary completion date | February 28, 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years and older |
Eligibility | Inclusion Criteria: - Male or female subjects, 12 years of age or older as of the Screening Visit (SV) - General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the subject at increased risk during the study - A history of PAR to a relevant perennial allergen for a minimum of two years immediately preceding the study Screening Visit (SV). The PAR must have been of sufficient severity to have required treatment (either continuous or intermittent) in the past, and in the investigator's judgment is expected to require treatment throughout the entire study - A demonstrated sensitivity to at least one allergen known to induce PAR through a standard skin prick test. A positive test is defined as a wheal diameter at least 3 mm larger than the diluent control wheal for the skin prick test. Documentation of a positive result 12 months prior to Screening Visit (SV) is acceptable - Other criteria apply Exclusion Criteria: - History of physical findings of nasal pathology, including nasal polyps or other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma, including nasal piercing, or surgery and atrophic rhinitis or rhinitis medicamentosa (all within the last 60 days prior to Screening Visit [SV]) - Participation in any investigational drug study within the 30 days preceding the Screening Visit (SV) or planned participation in another investigational drug study at any time during this study - History of a respiratory infection or disorder (including, but not limited to bronchitis, pneumonia, chronic sinusitis, or influenza within the 14 days preceding the Screening Visit (SV) or development of a respiratory infection during the Run-In Period - Active asthma requiring treatment with inhaled or systemic corticosteroids and/or routine use of ß-agonists and any controller drugs (e.g., theophylline, leukotriene antagonists). History of intermittent use (less than or equal to 3 uses per week) of inhaled short acting beta-agonists prior to the Screening Visit (SV) is acceptable. - Other criteria apply Randomization Criteria - Subject continues to be in general good health, meeting the selection criteria - Subject has a minimum subject-reported reflective TNSS of an average of 5 (out of a possible 12) on the last 7 days during the Run-In Period - The subject-reported scores for rhinorrhea or nasal congestion must be an average of 2 or greater during the last 7 days of the Run-In Period - Each subject must have adequately completed the electronic AR Assessment Diary (failure is defined as missing the diary entry on more than 2 calendar days during the last 7 days of the Run-In Period) - Other criteria apply |
Country | Name | City | State |
---|---|---|---|
United States | Teva Clinical Study Site | Atlanta | Georgia |
United States | Teva Clinical Study Site | Bethlehem | Pennsylvania |
United States | Teva Clinical Study Site | Bozeman | Montana |
United States | Teva Clinical Study Site | Cincinnati | Ohio |
United States | Teva Clinical Study Site | Collegeville | Pennsylvania |
United States | Teva Clinical Study Site | Colorado Springs | Colorado |
United States | Teva Clinical Study Site | Dallas | Texas |
United States | Teva Clinical Study Site | El Paso | Texas |
United States | Teva Clinical Study Site | Encinitas | California |
United States | Teva Clinical Study Site | Eugene | Oregon |
United States | Teva Clinical Study Site | Greenfield | Wisconsin |
United States | Teva Clinical Study Site | High Point | North Carolina |
United States | Teva Clinical Study Site | Houston | Texas |
United States | Teva Clinical Study Site | Huntington Beach | California |
United States | Teva Clinical Study Site | Kerrville | Texas |
United States | Teva Clinical Study Site | Lenexa | Kansas |
United States | Teva Clinical Study Site | Metairie | Louisiana |
United States | Teva Clinical Study Site | Minneapolis | Minnesota |
United States | Teva Clinical Study Site | Normal | Illinois |
United States | Teva Clinical Study Site | North Syracuse | New York |
United States | Teva Clinical Study Site | Overland Park | Kansas |
United States | Teva Clinical Sudy Site | Oxford | Alabama |
United States | Teva Clinical Study Site | Plymouth | Minnesota |
United States | Teva Clinical Study Site | Rochester | New York |
United States | Teva Clinical Study Site | Rockville Center | New York |
United States | Teva Clinical Study Site | San Antonio | Texas |
United States | Teva Clinical Study Site | San Diego | California |
United States | Teva Clinical Study Site | Stockbridge | Georgia |
United States | Teva Clinical Study Site | Stockton | California |
United States | Teva Clinical Study Site | Sylvania | Ohio |
United States | Teva Clinical Study Site | Vancouver | Washington |
United States | Teva Clinical Study Site | West Allis | Wisconsin |
United States | Teva Clinical Study Site | Wheaton | Maryland |
United States | Teva Clinical Study Site | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
Teva Branded Pharmaceutical Products R&D, Inc. |
United States,
Carr W, Meltzer EO, Finn A, Dorinsky PM, Kelley L, Dunbar SA, Tantry SK. Effective nasal symptom relief and improvement in health-related quality of life in subjects with perennial allergic rhinitis following 6-week once-daily treatment with beclomethason
Gross GN, Settipane RA, Ford LB, Kelley L, Dunbar SA, Tantry SK, Dorinsky PM . Patient Satisfaction and Ease-of-Use of BDP HFA Nasal Aerosol Device in Subjects With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol 2011 (Supplement); 107(11):A119 -
Meltzer EO, Jacobs RL, LaForce CF, Dorinsky PM, Kelley L, Dunbar SA, Tantry SK. . BDP HFA Nasal Aerosol 320 µg Once Daily Is Safe and Effective in the Treatment of Nasal Symptoms Associated With Perennial Allergic Rhinitis. Ann Allergy Asthma Immunol 2011
Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc. 2012 May-Jun;33(3):249-57. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks | Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale:
0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement. |
Baseline (Days -6 to 0), Day 1 to Week 30 | |
Secondary | Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 30 Weeks | Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale:
0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement. |
Baseline (Days -6 to 0), Day 1 to Week 30 | |
Secondary | Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 52 Weeks | Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 24-hours (prior to the assessment) daily using the following scale:
0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement. |
Baseline (Days -6 to 0), Day 1 to Week 52 | |
Secondary | Change From Baseline in Average Subject-Assessed 24-Hour Instantaneous Total Nasal Symptom Score (iTNSS) up to 52 Weeks | Participants recorded the severity of their nasal symptoms (sneezing, runny nose, itchy nose and nasal congestion) in the past 10 minutes (prior to the assessment) daily using the following scale:
0=absent (no sign/symptom); 1=mild (sign/symptom present, easily tolerated); 2=moderate (bothersome but tolerable); 3=severe (hard to tolerate, interfere with daily activities). The total nasal symptom score (sum of 4 symptom scores) ranges from 0 to 12 (worst symptoms). A negative change from baseline score indicates improvement. |
Baseline (Days -6 to 0), Day 1 to Week 52 | |
Secondary | Change From Baseline to Week 30 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline | The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7.
Week 30 scores were compared to baseline scores. A negative change score indicates improvement. |
Day 0 (Baseline) and Week 30 | |
Secondary | Change From Baseline to Week 52 in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) in Participants With Impaired Quality of Life at Baseline | The adult RQLQ has 28 questions in 7 domains (activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional). Participants were asked to recall their experiences during the previous week and to give their responses on a 7-point scale (0 = Least severe to 6 = Extremely severe). The overall RQLQ score is the mean of all 28 responses, and ranges from 0 to 7.
Week 52 scores were compared to baseline scores. A negative change score indicates improvement. |
Day 0 (Baseline) and Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02443805 -
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
|
Phase 3 | |
Completed |
NCT01231464 -
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00224523 -
Long Term Safety Of GW685698X Via Nasal Biopsy
|
Phase 3 | |
Completed |
NCT00232518 -
Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis
|
N/A | |
Completed |
NCT00658918 -
To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)
|
Phase 3 | |
Completed |
NCT00404586 -
Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber
|
Phase 1 | |
Withdrawn |
NCT02988778 -
Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT01678807 -
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
|
Phase 1 | |
Completed |
NCT01644617 -
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
|
Phase 2 | |
Completed |
NCT01216384 -
Single Rising Dose (SRD), Multiple Rising Dose (MRD) Study of BI 671800 in Healthy Asian Volunteers
|
Phase 1 | |
Completed |
NCT00848965 -
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
|
Phase 4 | |
Completed |
NCT00092118 -
The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)
|
Phase 3 | |
Completed |
NCT00839189 -
Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults
|
Phase 1 | |
Completed |
NCT00570492 -
Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.
|
Phase 4 | |
Completed |
NCT00806754 -
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
|
Phase 4 | |
Recruiting |
NCT00153595 -
EWO1 in Persistent Allergic Rhinitis Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00132925 -
An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT02498509 -
Clinical Trial to Evaluate the Efficacy and Safety of CKD-342
|
Phase 3 | |
Completed |
NCT01134705 -
Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)
|
Phase 3 | |
Completed |
NCT02238236 -
Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus
|
N/A |